These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26424330)

  • 21. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
    Shomali ME; Ørsted DD; Cannon AJ
    Diabet Med; 2017 Feb; 34(2):197-203. PubMed ID: 27412701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.
    Wei W; Buysman E; Grabner M; Xie L; Brekke L; Ke X; Chu JW; Levin PA
    Diabetes Obes Metab; 2017 Mar; 19(3):375-386. PubMed ID: 27860158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
    Nauck M; Marre M
    Postgrad Med; 2009 May; 121(3):5-15. PubMed ID: 19491535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
    Chitnis AS; Ganz ML; Benjamin N; Langer J; Hammer M
    Adv Ther; 2014 Sep; 31(9):986-99. PubMed ID: 25245811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
    Kaku K; Rasmussen MF; Clauson P; Seino Y
    Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
    Takase T; Nakamura A; Yamamoto C; Nomoto H; Miya A; Dannoura M; Cho KY; Kurihara Y; Manda N; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 May; 10(3):699-705. PubMed ID: 30076787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
    Lane W; Weinrib S; Rappaport J; Hale C
    Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
    Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
    Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
    Harder H; Nielsen L; Tu DT; Astrup A
    Diabetes Care; 2004 Aug; 27(8):1915-21. PubMed ID: 15277417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
    Niswender K; Pi-Sunyer X; Buse J; Jensen KH; Toft AD; Russell-Jones D; Zinman B
    Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.